The emergence of effective vaccines for COVID-19 has been welcomed by the world with great optimism. Given their increased susceptibility to COVID-19, the question arises whether individuals with type-2 diabetes mellitus (T2DM) and other metabolic conditions can respond effectively to the mRNA-based vaccine. We aimed to evaluate the levels of anti-SARS-CoV-2 IgG and neutralizing antibodies in people with T2DM and/or other metabolic risk factors (hypertension and obesity) compared to those without. This study included 262 people (81 diabetic and 181 non-diabetic persons) that took two doses of BNT162b2 (Pfizer–BioNTech) mRNA vaccine. Both T2DM and non-diabetic individuals had a robust response to vaccination as demonstrated by their high antibody titers. However, both SARS-CoV-2 IgG and neutralizing antibodies titers were lower in people with T2DM. The mean ( ± 1 standard deviation) levels were 154 ± 49.1 vs. 138 ± 59.4 BAU/ml for IgG and 87.1 ± 11.6 vs. 79.7 ± 19.5% for neutralizing antibodies in individuals without diabetes compared to those with T2DM, respectively. In a multiple linear regression adjusted for individual characteristics, comorbidities, previous COVID-19 infection, and duration since second vaccine dose, diabetics had 13.86 BAU/ml (95% CI: 27.08 to 0.64 BAU/ml, p=0.041) less IgG antibodies and 4.42% (95% CI: 8.53 to 0.32%, p=0.036) fewer neutralizing antibodies than non-diabetics. Hypertension and obesity did not show significant changes in antibody titers. Taken together, both type-2 diabetic and non-diabetic individuals elicited strong immune responses to SARS-CoV-2 BNT162b2 mRNA vaccine; nonetheless, lower levels were seen in people with diabetes. Continuous monitoring of the antibody levels might be a good indicator to guide personalized needs for further booster shots to maintain adaptive immunity. Nonetheless, it is important that people get their COVID-19 vaccination especially people with diabetes.
【저자키워드】 COVID-19, antibodies, Vaccine, COVID-19 vaccine, mRNA vaccine, BNT162b2, Diabetes mellitus type 2, T2D, 【초록키워드】 neutralizing antibody, IgG, adaptive, Immunity, antibody, susceptibility, obesity, Comorbidities, diabetes, hypertension, vaccine dose, IgG antibody, Characteristics, COVID-19 vaccination, COVID-19 infection, anti-SARS-CoV-2 IgG, mRNA, SARS-CoV-2 IgG, Antibody titers, booster, dose, Multiple linear regression, Diabetic, optimism, Standard deviation, Type-2 diabetes mellitus, diabetics, individual, Pfizer–BioNTech, mRNA-based vaccine, strong immune response, robust, significant changes in, evaluate, adjusted, less, question, demonstrated, maintain, effective vaccine, elicited, respond, diabete, arise, Continuous, metabolic condition, metabolic risk factor, neutralizing antibodies titer, of BNT162b2, response to vaccination, SARS-CoV-2 BNT162b2, 【제목키워드】 BNT162b2 mRNA, individual, Level,